Continued investment in research and development
First written in FY2019-Q3. . Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Annual R&D expenses decreasedAnnual report
「The Group's total R&D expenses for the fiscal year were ¥1,316 million.」
Annual R&D expenses were ¥1,316 million, down from ¥1,413 million in the previous fiscal year. Meanwhile, the Group continued development of IPX-100, ignis, medical cameras and inspection equipment. - FY2026-H1R&D expenses for the interim period: ¥550 millionAnnual report
「Total R&D expenses for the six-month consolidated accounting period were ¥550 million.」
Total R&D expenses for the six-month consolidated accounting period were ¥550 million. - FY2025Annual R&D expenses decreasedAnnual report
「The Group's total R&D expenses for the fiscal year were ¥1,413 million.」
Annual R&D expenses were ¥1,413 million, down from ¥1,651 million in the previous fiscal year. Meanwhile, the Group continued development of MoIP, 4K/HD cameras, inspection equipment and medical devices. - FY2025-H1R&D expenses for the interim period: ¥753 millionAnnual report
「Total R&D expenses for the six-month consolidated accounting period were ¥753 million.」
Total R&D expenses for the six-month consolidated accounting period were ¥753 million. - FY2024-Q3R&D expenses for the nine-month period: ¥1,224 millionAnnual report
「Total R&D expenses for the nine-month period ended December 31 were ¥1,224 million.」
Total R&D expenses for the nine-month consolidated period were ¥1,224 million. - FY2024-Q2R&D expenses for the six-month period: ¥809 millionAnnual report
「Total R&D expenses for the six-month period ended September 30 were ¥809 million.」
¥809 million was recorded as total R&D expenses for the six-month consolidated period. - FY2024-Q1First-quarter R&D expenses: ¥392 millionAnnual report
「Total R&D expenses for the three-month period ended June 30 were ¥392 million.」
¥392 million was recorded as total R&D expenses for the three-month consolidated period. - FY2023-Q3R&D expenses for the nine-month period: ¥1,198 millionAnnual report
「Total R&D expenses for the nine-month period ended December 31 were ¥1,198 million.」
¥1,198 million was recorded as total R&D expenses for the nine-month consolidated period. - FY2023-Q2R&D expenses for the six-month period: ¥790 millionAnnual report
「Total R&D expenses for the six-month period ended September 30 were ¥790 million.」
Total R&D expenses for the six-month consolidated period were ¥790 million. - FY2023-Q1First-quarter R&D expenses: ¥402 millionAnnual report
「Total R&D expenses for the three-month period ended June 30 were ¥402 million.」
Total R&D expenses for the three-month consolidated period were ¥402 million, down from ¥479 million in the same period of the previous year. - FY2022-Q3R&D expenses for the nine-month period: ¥1,301 millionAnnual report
「Total R&D expenses for the nine-month period ended December 31 were ¥1,301 million.」
Total R&D expenses for the nine-month consolidated period were ¥1,301 million, down from ¥1,459 million in the same period of the previous year. - FY2022-Q2R&D expenses for the six-month period: ¥827 millionAnnual report
「Total R&D expenses for the six-month period ended September 30 were ¥827 million.」
¥827 million was recorded as total R&D expenses for the six-month consolidated period. - FY2022-Q1First-quarter R&D expenses: ¥416 millionAnnual report
「Total R&D expenses for the three-month period ended June 30 were ¥416 million.」
Total R&D expenses for the three-month consolidated period were ¥416 million, down from ¥479 million in the same period of the previous year. - FY2021Annual R&D Expenditure IncreasedAnnual report
「The Group's total R&D expenses for the fiscal year were ¥1,995 million.」
Annual R&D expenses were ¥1,995 million, up from ¥1,639 million in the previous fiscal year. The Group continued development of 4K and 8K products, MoIP, security systems, medical products and inspection equipment. - FY2021-Q3R&D expenses for the nine-month period: ¥1,459 millionAnnual report
「Total R&D expenses for the nine-month period ended December 31 were ¥1,459 million.」
¥1,459 million was recorded as total R&D expenses for the nine-month consolidated period. - FY2021-Q2R&D expenses for the six-month period: ¥962 millionAnnual report
「Total R&D expenses for the six-month period ended September 30 were ¥962 million.」
¥962 million was recorded as total R&D expenses for the six-month consolidated period. - FY2021-Q1First-quarter R&D expenses: ¥479 millionAnnual report
「Total R&D expenses for the three-month period ended June 30 were ¥479 million.」
R&D expenses for the three-month consolidated period were ¥479 million, up from ¥390 million in the same period of the previous year. - FY2020Annual R&D expenses: ¥1,639 millionAnnual report
「The Group's total R&D expenses for the fiscal year were ¥1,639 million.」
Annual R&D expenses were ¥1,639 million, down from ¥1,776 million in the previous fiscal year. The Group continued to invest in development of 4K and 8K products, remote cameras, security systems, medical 8K products and inspection equipment. - FY2020-Q3R&D expenses for the nine-month period: ¥1,178 millionAnnual report
「Total R&D expenses for the nine-month period ended December 31 were ¥1,178 million.」
¥1,178 million was recorded as total R&D expenses for the nine-month consolidated period. - FY2020-Q2R&D expenses for the six-month period: ¥778 millionAnnual report
「Total R&D expenses for the six-month period ended September 30 were ¥778 million.」
¥778 million was recorded as total R&D expenses for the six-month consolidated period. - FY2020-Q1First-quarter R&D expenses: ¥390 millionAnnual report
「Total R&D expenses for the three-month period ended June 30 were ¥390 million.」
¥390 million was recorded as total R&D expenses for the three-month consolidated period. - FY2019-Q3First statedAnnual report
「Total R&D expenses for the nine-month period ended December 31 were ¥1,333 million.」
¥1,333 million was recorded as total R&D expenses for the nine-month consolidated period.